Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Chenguang Medical Technologies Co (BJSE:920300) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Shanghai Chenguang Medical Technologies Co EBITDA Margin % Related Terms
Shanghai Chenguang Medical Technologies Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Chenguang Medical Technologies Co EBITDA Margin % Chart
Shanghai Chenguang Medical Technologies Co Annual Data
BJSE:920300 vs VRT, BE: EBITDA Margin % Comparison
For the Electrical Equipment & Parts subindustry, Shanghai Chenguang Medical Technologies Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Chenguang Medical Technologies Co EBITDA Margin % vs Industrial Products Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Chenguang Medical Technologies Co (BJSE:920300) has a EBITDA Margin % of -25.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Chenguang Medical Technologies Co and its competitors. According to the industry distribution chart, Shanghai Chenguang Medical Technologies Co ranks #2881 out of 3040 companies in the Industrial Products industry, placing it in the top 94.8%.
Is Shanghai Chenguang Medical Technologies Co's EBITDA Margin % too high?
Shanghai Chenguang Medical Technologies Co's current EBITDA Margin % is -25.37%. Based on the distribution chart, Shanghai Chenguang Medical Technologies Co ranks #2881 out of 3040 companies in the Industrial Products industry, which is in the bottom quartile relative to peers. Overall, Shanghai Chenguang Medical Technologies Co has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Chenguang Medical Technologies Co's EBITDA Margin % compare to VRT and BE?
According to the Industrial Products industry distribution chart, Shanghai Chenguang Medical Technologies Co ranks #2881 out of 3040 companies for EBITDA Margin %. This places Shanghai Chenguang Medical Technologies Co in the lower half of its industry. The industry median EBITDA Margin % is 9.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Industrial Products company?
The median EBITDA Margin % among Industrial Products companies is 9.62, based on 3,040 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Shanghai Chenguang Medical Technologies Co and its competitors. For the Industrial Products industry, the median EBITDA Margin % is 9.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Chenguang Medical Technologies Co's current EBITDA Margin % is -25.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Chenguang Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Chenguang Medical Technologies Co (BJSE:920300) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥6.57, compared to a current price of ¥9.47 — trading 44.1% above its estimated fair value. The current EBITDA Margin % is -25.37%. Shanghai Chenguang Medical Technologies Co's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Shanghai Chenguang Medical Technologies Co (BJSE:920300), the current EBITDA Margin % is -25.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Chenguang Medical Technologies Co (BJSE:920300) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Chenguang Medical Technologies Co stock appears to be overvalued.
The current stock price of ¥9.47 is trading 44.1% above its estimated GF Value™ of ¥6.57.
GuruFocus considers Shanghai Chenguang Medical Technologies Co to be Significantly Overvalued.
Key valuation signals for BJSE:920300:
EBITDA Margin %: -25.37%
GF Value™: ¥6.57 vs. price of ¥9.47 (44.1% above fair value)
No single metric tells the full story. See the BJSE:920300 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Chenguang Medical Technologies Co Ltd engages in research and development, production, and sales of the core hardware of medical imaging superconducting MRI equipment and special magnets in the field of scientific research. The company's product system covers hardware of superconducting MRI devices, including: RF detectors, superconducting magnets, gradient coils, RF amplifiers, gradient amplifiers.
53GF Score
Get the complete analysis for BJSE:920300
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920300 has been successfully added to your 
